Palleon Pharmaceuticals

Executive Summary

Palleon Pharmaceuticals is a private biotechnology company pioneering a novel class of immunotherapies targeting glyco-immune checkpoints. Founded in 2015 and headquartered in Waltham, Massachusetts, Palleon leverages its proprietary EAGLE platform to develop enzyme-antibody fusion proteins designed to degrade immunosuppressive sialoglycans on pathogenic cells. The company's pipeline spans both oncology and autoimmune diseases, addressing key unmet needs in immune evasion and dysregulation. By modulating the glyco-immune axis, Palleon aims to overcome resistance in cancer immunotherapy and selectively deplete pathogenic immune cells in autoimmune conditions. While the company remains in preclinical to early clinical stages, its differentiated approach could position it as a leader in the emerging field of glycobiology-based therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1/2 trial for lead oncology candidate40% success
• Q4 2026Preclinical data presentation for autoimmune program at major conference60% success
• Q2 2026Partnership or financing announcement to support pipeline advancement50% success